Objectives. - To evaluate the effectiveness, the costs and savings of hepat
itis C screening strategies according to seroprevalence.
Methods. - A decision analysis was performed to compare the cost and effect
iveness between various screening strategies and the current strategy that
implies no screening. Effectiveness was defined as the number of avoided pa
thologies as a result of screening. Benefits due to early screening and tre
atment were evaluated as avoided costs and were taking into account in the
net costs. Two hypotheses were proposed for the treatment A disease history
model was developed in order to evaluate the long term consequences of a s
creening programme (over a 10 year period).
Results. - Status quo was dominated whatever screening strategies considere
d. The strategy consisting of an ELISA test confirmed by another ELISA was
the best strategy in term of cost-effectiveness. Tb screen and to treat wit
h interferon and ribavirine was a better option than adding ribavirine only
for relapse patients.
Conclusion. - To screen and treat infected HCV patients would be cost-savin
gs if we compare with status quo. (C) 1999 Elsevier; Paris.